Time filter

Source Type

Exton, PA, United States

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus and hepatitis C virus infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008. Wikipedia.

Jacobsen T.,ViroPharma | Sifontis N.,Temple University
American Journal of Health-System Pharmacy | Year: 2010

Purpose. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus (CMV) infection are described. Summary. The use of current antiviral treatments for CMV in patients undergoing solid organ or hematopoietic stem cell transplantation is categorically characterized by high-toxicity profiles and drug-drug interactions. The consequences of hematologic toxicities may be manifested clinically in several ways, including increased rates of infections and bleeding, more pronounced bone marrow suppression, and the development of anemia. Moreover, patients undergoing solid organ or stem cell transplantation have difficulty tolerating the nephrotoxic effects of current treatments, because their renal function is often already compromised by infection, sepsis, or the administration of other commonly used nephrotoxic drugs. Patients undergoing transplantation have an especially high risk of drug interactions, because multiple drugs are often administered to prevent allograft rejection, to treat or prevent infection, to control pain, and to treat a number of possible comorbid conditions. Commonly used antiviral agents for the management of CMV infection include cidofovir, CMV i.v. immunoglobulin, foscarnet, ganciclovir, and valganciclovir. Drug interactions associated with the use of ganciclovir and foscarnet sodium are numerous and potentially dangerous. At this time, such toxicities are managed by dosage adjustments, temporary discontinuations of medications, and careful monitoring of the patient. Conclusion. Clinically important drug-drug interactions can occur in immunocompromised transplant recipients who are treated for CMV infection. Because of the high toxicity and narrow therapeutic range of the antiviral medications available for CMV management, patients should be carefully monitored for any potential adverse effects from such interactions. Copyright © 2010, American Society of Health-System Pharmacists, Inc. All rights reserved.

Zilberberg M.D.,University of Massachusetts Amherst | Zilberberg M.D.,EviMed Research Group LLC | Tillotson G.S.,ViroPharma | McDonald L.C.,Centers for Disease Control and Prevention
Emerging Infectious Diseases | Year: 2010

We evaluated the annual rate (cases/10,000 hospitalizations) of pediatric hospitalizations with Clostridium difficile infection (CDI; International Classifi cation of Diseases, 9th revision, clinical modifi cation code 008.45) in the United States. We performed a time-series analysis of data from the Kids' Inpatient Database within the Health Care Cost and Utilization Project during 1997-2006 and a cross-sectional analysis within the National Hospital Discharge Survey during 2006. The rate of pediatric CDI-related hospitalizations increased from 7.24 to 12.80 from 1997 through 2006; the lowest rate was for children <1 year of age. Although incidence was lowest for newborns (0.5), incidence for children <1 year of age who were not newborns (32.01) was similar to that for children 5-9 years of age (35.27), which in turn was second only to incidence for children 1-4 years of age (44.87). Pediatric CDI-related hospitalizations are increasing. A better understanding of the epidemiology and outcomes of CDI is urgently needed.

Jacobs J.,Allergy and Asthma Clinical Research Inc. | Jacobs J.,ViroPharma
Allergy and Asthma Proceedings | Year: 2011

Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis. Patients with novel mutations may experience especially long delays in diagnosis due to a lack of family history. This case demonstrates one such case in which diagnosis was delayed for many years. Improved physician awareness of the signs and symptoms of hereditary angioedema may prevent such delay for patients with this disorder in the future. Abdominal pain, angioedema, bradykinin, C1 inhibitor, hereditary, inherited, swelling. Copyright © 2011, OceanSide Publications, Inc., U.S.A.

Compositions and methods for inhibiting

A method and composition for treating or preventing antibody-mediated rejection (AMR) of a transplanted organ are provided.

Discover hidden collaborations